Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MPLT by emailGet an email when MPLT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MPLT, unsubscribe in one click. Privacy
📣 What MPLT Says Is Next
second half of 2027 · “Topline results from VISTA are expected in the second half of 2027.”
Company press release, Aug 13, 2026 · SEC filing
in 2028 · “The Company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, including the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.”
Company press release, Aug 13, 2026 · SEC filing
second half of 2027 · “In ADP, enrollment in VISTA remains ongoing, with topline results expected in the second half of 2027.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MPLT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MPLT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.